Rationale for targeting pepsin in the treatment of reflux disease

Annals of Otology, Rhinology and Laryngology

Volumn 119, Issue 8, 2010, Pages 547-558

  Johnston, Nikki ^a   Wells, Clive W ^a   Samuels, Tina L ^a   Blumin, Joel H ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Laryngopharyngeal reflux; Pepsin; Reflux

Indexed keywords

CLATHRIN; PEPSIN A; PROTEIN RAB 9; RAB PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENDOCYTOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LARYNGEAL BIOPSY; LARYNGOPHARYNGEAL REFLUX; PRIORITY JOURNAL;

EID: 77955385732     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348941011900808     Document Type: Article

References (34)

1. Altman KW, Stephens RM, Lyttle CS, Weiss KB. Changing impact of gastroesophageal reflux in medical and otolaryngology practice. Laryngoscope 2005;115:1145-53.
2. Bercin S, Kutluhan A, Yurttas V, Yalciner G, Bozdemir K, Sari N. Evaluation of laryngopharyngeal reflux in patients with suspected laryngopharyngeal reflux, chronic otitis media and laryngeal disorders. Eur Arch Otorhinolaryngol 2008;265:1539-43.
3. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991;101:1-78.
4. Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg 2002;127:32-5.
5. Qadeer MA, Colabianchi N, Vaezi MF. Is GERD a risk factor for laryngeal cancer? Laryngoscope 2005;115:486-91.
6. Ali Mel-S. Laryngopharyngeal reflux: diagnosis and treat ment of a controversial disease. Curr Opin Allergy Clin Immunol 2008;8:28-33.
7. Sataloff RT. Laryngopharyngeal reflux: concepts and con troversies. Ear Nose Throat J 2008;87:549-54.
8. Reimer C, Bytzer P. Management of laryngopharyngeal reflux with proton pump inhibitors. Ther Clin Risk Manag 2008;4:225-33. (Pubitemid 351460947)
9. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006;116:254-60.
10. Reichel O, Dressel H, Wiederänders K, Issing WJ. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. Otolaryngol Head Neck Surg 2008;139:414-20.
11. Tamhankar AP, Peters JH, Portale G, et al. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg 2004;8:890-8.
12. Kawamura O, Aslam M, Rittmann T, Hofmann C, Shaker R. Physical and pH properties of gastroesophagopharyngeal refluxate: a 24-hour simultaneous ambulatory impedance and pH monitoring study. Am J Gastroenterol 2004;99:1000-10. (Pubitemid 38917800)
13. Oelschlager BK, Quiroga E, Isch JA, Cuenca-Abente F. Gastroesophageal and pharyngeal reflux detection using impedance and 24-hour pH monitoring in asymptomatic subjects: defining the normal environment. J Gastrointest Surg 2006;10:54-62. (Pubitemid 41820588)
14. Sharma N, Agrawal A, Freeman J, Vela MF, Castell D. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008;6:521-4.
15. Tutuian R, Vela MF, Hill EG, Mainie I, Agrawal A, Castell DO. Characteristics of symptomatic reflux episodes on acid suppressive therapy. Am J Gastroenterol 2008;103:1090-6. (Pubitemid 351677992)
16. Kivilaakso E, Fromm D, Silen W. Effect of bile salts and related compounds on isolated esophageal mucosa. Surgery 1980;87:280-5. (Pubitemid 10176052)
17. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999;44:598-602. (Pubitemid 29195903)
18. Johnston N, Wells CW, Samuels TL, Blumin JH. Pepsin in nonacidic refluxate can damage hypopharyngeal epithelial cells. Ann Otol Rhinol Laryngol 2009;118:677-85.
19. Johnston N, Dettmar PW, Bishwokarma B, Lively MO, Koufman JA. Activity/stability of human pepsin: implications for reflux attributed laryngeal disease. Laryngoscope 2007;117:1036-9.
20. Johnston N, Dettmar PW, Lively MO, et al. Effect of pepsin on laryngeal stress protein (Sep70, Sep53, and Hsp70) response: role in laryngopharyngeal reflux disease. Ann Otol Rhinol Laryngol 2006;115:47-58. (Pubitemid 43132441)
21. Johnston N, Knight J, Dettmar PW, Lively MO, Koufman J. Pepsin and carbonic anhydrase isoenzyme III as diagnostic markers for laryngopharyngeal reflux disease. Laryngoscope 2004;114:2129-34. (Pubitemid 39602477)
22. Johnston N, Wells CW, Blumin JH, Toohill RJ, Merati AL. Receptor-mediated uptake of pepsin by laryngeal epithelial cells. Ann Otol Rhinol Laryngol 2007;116:934-8. (Pubitemid 350308794)
23. Samuels TL, Johnston N. Pepsin as a marker of extraesophageal reflux. Ann Otol Rhinol Laryngol 2010;119:203-8.
24. Iqbal M, Batch AJ, Moorthy K, Cooper BT, Spychal RT. Outcome of surgical fundoplication for extra-oesophageal symptoms of reflux. Surg Endosc 2009;23:557-61.
25. Duffy JP, Maggard M, Hiyama DT, et al. Laparoscopic Nissen fundoplication improves quality of life in patients with atypical symptoms of gastroesophageal reflux. Am Surg 2003;69:833-8.
26. Fernando HC, El-Sherif A, Landreneau RJ, et al. Efficacy of laparoscopic fundoplication in controlling pulmonary symptoms associated with gastroesophageal reflux disease. Surgery 2005;138:612-7. (Pubitemid 41546182)
27. Piper DW, Fenton BH. pH stability and activity curves of pepsin with special reference to their clinical importance. Gut 1965;6:506-8.
28. Berryman MA, Rodewald RD. An enhanced method for post-embedding immunocytochemical staining which preserves cell membranes. J Histochem Cytochem 1990;38:159-70.
29. Burleigh BA, Wells CW, Clarke MW, Gardiner PR. An integral membrane glycoprotein associated with an endocytic compartment of Trypanosoma vivax: identification and partial char acterization. J Cell Biol 1993;120:339-52.
30. Pastan I, Willingham MC, eds. Endocytosis. New York, NY: Plenum, 1985:1-44.
31. Maréchal V, Prevost MC, Petit C, Perret E, Heard JM, Schwartz O. Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis. J Virol 2001;75:11166-77. (Pubitemid 33031583)
32. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
33. Kjeken R, Mousavi SA, Brech A, Griffiths G, Berg T. Wortmannin-sensitive trafficking steps in the endocytic pathway in rat liver endothelial cells. Biochem J 2001;357:497-503. (Pubitemid 32701787)
34. Liu Y, Jiang N, Wu J, Dai W, Rosenblum JS. Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J Biol Chem 2007;282:2505-11. (Pubitemid 47076790)